-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2021, with the advancement of centralized procurement policies and medical insurance negotiations, the reform of the pharmaceutical industry has continued.
At the same time, the flow of talents in the pharmaceutical market is also accelerating
.
According to industry statistics, at least 238 A-share listed pharmaceutical companies have announced changes in their current executives since the beginning of the year, involving 667 executives, of which nearly 300 have resigned
.
Among the nearly 300 executives who resigned, the positions that have changed more include the chairman, vice president, general manager, deputy general manager, secretary of the board of directors, chief financial officer/director, etc.
, involving Hengrui Pharmaceuticals, Bikang Pharmaceuticals, and Xinmai medical, biological families before, Hokuriku Pharmaceutical and other companies
.
Since November, the wave of resignations in the pharmaceutical industry has continued.
More than 10 companies including Hengrui Pharmaceutical, Lexin Medical, Wantai Bio, Kanghong Pharmaceutical, and Ruizhi Pharmaceutical have issued announcements on the resignation of senior executives
.
Among them, there are 3 chairman/vice-chairman changes, namely WOO SWEE LIAN, chairman of Ruizhi Pharmaceutical, Yao Jianlin, vice chairman of Jiangsu Wuzhong, and Xu Ziying, chairman of First Pharmaceutical
.
On November 1, Ruizhi Medicine issued an announcement stating that Mr.
WOO SWEE LIAN had applied to resign from the company's chairman, director, and chairman of the board's strategy committee due to personal reasons, and continued to serve as the company's strategic consultant after resignation
.
In addition, after review by the board of directors, it was agreed to nominate Fan Shixin as a candidate for non-independent director of the company's fifth board of directors
.
Jiangsu Wuzhong issued an announcement on the evening of November 11, stating that Mr.
Yao Jianlin had applied for resignation from the company's vice chairman and director due to his reaching retirement age.
At the same time, he also resigned as a member of the company's board of directors, corporate development and strategic investment committee
.
On November 12, First Pharmaceutical issued an announcement stating that due to work reasons, Ms.
Xu Ziying had applied to resign from the company's 9th board of directors, director, chairman of the board's strategy committee, and member of the remuneration and appraisal committee
.
After resignation, Ms.
Xu Ziying no longer holds any position in the company
.
It is worth mentioning that since November, many senior executives of Lexin Medical have undergone changes.
.
Specifically: Xu Lang resigned as deputy general manager and secretary of the board of directors due to personal reasons; Mai Jiongzhang resigned as general manager due to the adjustment of the company's business management structure; Shi Shaohai resigned as chief financial officer and deputy general manager due to job adjustment; 2021 Starting from November 10, Feng Yongwei has assumed the position of deputy general manager and chief financial officer, Wang Qingyu has assumed the position of general manager, and Zhong Ling has assumed the position of deputy general manager and secretary of the board of directors, taking office on November 10, 2021
.
From the performance point of view, in the first three quarters of this year, Lexin Medical's revenue was 1.
276 billion yuan, a year-on-year increase of 50%; net profit was 38.
47 million yuan, a year-on-year decrease of 28%
.
It is reported that the company's net profit has declined for two consecutive quarters.
The net profit in the second quarter was 7.
52 million yuan, down 63% year-on-year, and the net profit in the third quarter was 17.
96 million yuan, down 36% year-on-year
.
In this regard, Lexin Medical said in its third quarterly report that it was mainly due to the increase in raw material prices, exchange rate changes, the company’s increased investment in strategic business, and in order to maintain the company’s mid- to long-term competitive advantage and sustainable growth, the company continued to increase research and development and Management investment and short-term pressure on profits
.
However, in the survey, the company mentioned when answering investors’ questions that the smart wearable business, as an important part of Lexin Healthcare’s IoT strategic layout, increased its sales revenue in the first three quarters of this year, and its share increased
.
In addition, it told the relevant media that in the field of smart wear, due to the emergence of many promotional activities in Q4, it will usher in the peak season
.
At the same time, the flow of talents in the pharmaceutical market is also accelerating
.
According to industry statistics, at least 238 A-share listed pharmaceutical companies have announced changes in their current executives since the beginning of the year, involving 667 executives, of which nearly 300 have resigned
.
Among the nearly 300 executives who resigned, the positions that have changed more include the chairman, vice president, general manager, deputy general manager, secretary of the board of directors, chief financial officer/director, etc.
, involving Hengrui Pharmaceuticals, Bikang Pharmaceuticals, and Xinmai medical, biological families before, Hokuriku Pharmaceutical and other companies
.
Since November, the wave of resignations in the pharmaceutical industry has continued.
More than 10 companies including Hengrui Pharmaceutical, Lexin Medical, Wantai Bio, Kanghong Pharmaceutical, and Ruizhi Pharmaceutical have issued announcements on the resignation of senior executives
.
Among them, there are 3 chairman/vice-chairman changes, namely WOO SWEE LIAN, chairman of Ruizhi Pharmaceutical, Yao Jianlin, vice chairman of Jiangsu Wuzhong, and Xu Ziying, chairman of First Pharmaceutical
.
On November 1, Ruizhi Medicine issued an announcement stating that Mr.
WOO SWEE LIAN had applied to resign from the company's chairman, director, and chairman of the board's strategy committee due to personal reasons, and continued to serve as the company's strategic consultant after resignation
.
In addition, after review by the board of directors, it was agreed to nominate Fan Shixin as a candidate for non-independent director of the company's fifth board of directors
.
Jiangsu Wuzhong issued an announcement on the evening of November 11, stating that Mr.
Yao Jianlin had applied for resignation from the company's vice chairman and director due to his reaching retirement age.
At the same time, he also resigned as a member of the company's board of directors, corporate development and strategic investment committee
.
On November 12, First Pharmaceutical issued an announcement stating that due to work reasons, Ms.
Xu Ziying had applied to resign from the company's 9th board of directors, director, chairman of the board's strategy committee, and member of the remuneration and appraisal committee
.
After resignation, Ms.
Xu Ziying no longer holds any position in the company
.
It is worth mentioning that since November, many senior executives of Lexin Medical have undergone changes.
.
Specifically: Xu Lang resigned as deputy general manager and secretary of the board of directors due to personal reasons; Mai Jiongzhang resigned as general manager due to the adjustment of the company's business management structure; Shi Shaohai resigned as chief financial officer and deputy general manager due to job adjustment; 2021 Starting from November 10, Feng Yongwei has assumed the position of deputy general manager and chief financial officer, Wang Qingyu has assumed the position of general manager, and Zhong Ling has assumed the position of deputy general manager and secretary of the board of directors, taking office on November 10, 2021
.
From the performance point of view, in the first three quarters of this year, Lexin Medical's revenue was 1.
276 billion yuan, a year-on-year increase of 50%; net profit was 38.
47 million yuan, a year-on-year decrease of 28%
.
It is reported that the company's net profit has declined for two consecutive quarters.
The net profit in the second quarter was 7.
52 million yuan, down 63% year-on-year, and the net profit in the third quarter was 17.
96 million yuan, down 36% year-on-year
.
In this regard, Lexin Medical said in its third quarterly report that it was mainly due to the increase in raw material prices, exchange rate changes, the company’s increased investment in strategic business, and in order to maintain the company’s mid- to long-term competitive advantage and sustainable growth, the company continued to increase research and development and Management investment and short-term pressure on profits
.
However, in the survey, the company mentioned when answering investors’ questions that the smart wearable business, as an important part of Lexin Healthcare’s IoT strategic layout, increased its sales revenue in the first three quarters of this year, and its share increased
.
In addition, it told the relevant media that in the field of smart wear, due to the emergence of many promotional activities in Q4, it will usher in the peak season
.
